<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Ovarian Res</journal-id><journal-id journal-id-type="iso-abbrev">J Ovarian Res</journal-id><journal-title-group><journal-title>Journal of Ovarian Research</journal-title></journal-title-group><issn pub-type="epub">1757-2215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26400057</article-id><article-id pub-id-type="pmc">4579791</article-id><article-id pub-id-type="publisher-id">190</article-id><article-id pub-id-type="doi">10.1186/s13048-015-0190-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Ya-Qin</given-names></name><address><email>wangyaqin1039@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Jin</given-names></name><address><email>50375042@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Wang-Min</given-names></name><address><email>wmxu609@msn.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Qin-Zhen</given-names></name><address><email>qingzhenxie@hotmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Wen-Jie</given-names></name><address><email>523526931@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Geng-Xiang</given-names></name><address><email>402865302@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Jin</given-names></name><address><phone>+86 27 88041911-81115</phone><email>dryangqing@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Reproductive Medical center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060 China </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>8</volume><elocation-id>63</elocation-id><history><date date-type="received"><day>2</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>12</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Wang et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Ovarian stimulation in IVF cycle results in luteal supraphysiological steroid concentrations especially for high response patients. The aim of this study was to evaluate the efficacy of ovarian steroid hormone suppression in luteal phase after oocyte retrieval for preventing severe ovarian hyperstimulation syndrome (OHSS) in high-risk patients with embryo cryopreservation.</p></sec><sec><title>Methods</title><p>281 patients with high risk of OHSS were enrolled in this study among 4735 infertile women undergoing their first IVF treatment. The subjects were allocated into treatment and control group. The treatment group (<italic>n</italic>&#x02009;=&#x02009;161) received letrozole (<italic>n</italic>&#x02009;=&#x02009;43), mifepristone (<italic>n</italic>&#x02009;=&#x02009;51), cetrotide (<italic>n</italic>&#x02009;=&#x02009;39) and three-drug combinations (<italic>n</italic>&#x02009;=&#x02009;28) during the luteal phase after oocyte retrieval, respectively. The control group (<italic>n</italic>&#x02009;=&#x02009;120) received no medicine. Fertilization rate, good embryo rate, serum steroid concentration, clinical outcome, and incidence of severe OHSS were compared between the two groups.</p></sec><sec><title>Results</title><p>On days 2, 5 and 8 after oocyte retrieval, serum estradiol levels in the letrozole and three-drug combination therapy group were significantly lower than in the other three groups at the same time (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, respectively). There were no significantly difference of serum luteinizing hormone concentration on days 2, 5 and 8 and progesterone concentration on day 8 after oocyte retreival among the five groups (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05, respectively). Compared with the control group, the incidence of severe OHSS, the paracentesis rate, the duration of hospitalization and the days of luteal phase in each subgroup of treatment groups was not significantly decreased (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05, respectively).</p></sec><sec><title>Conclusions</title><p>Our findings indicate that steroidal ovarian suppression in luteal phase after oocyte retrieval seems to be unable to prevent severe OHSS in high-risk patients with embryo cryopreservation.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Ovarian hyperstimulation syndrome</kwd><kwd>In vitro fertilization</kwd><kwd>Luteal phase</kwd><kwd>Mifepristone</kwd><kwd>Aromatase inhibitors</kwd><kwd>Gonadotropin-releasing hormone antagonist</kwd><kwd>Prevention</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic and potentially life-threatening complication of induced ovulation. It is caused by an exaggerated response to gonadotropin-induced ovulation, such as the kind used during assisted reproductive technologies. The syndrome is characterized by cystic enlargement of the ovaries and an increase in capillary permeability, with the consequent acute third-space fluid sequestration and its related morbidity [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The prevention and mitigation of the incidence and severity of severe OHSS by whatever means would be a great boon to in vitro fertilization (IVF). Despite many years of clinical experience, the pathophysiology of OHSS is still obscure. Delaying embryo transfer with embryo cryopreservation can definitely avoid pregnancy-associated late OHSS. However, there are still no precise methods of completely eliminating the incidence of human chorionic gonadotrophin (hCG)-induced early severe OHSS [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>High estradiol (E<sub>2</sub>) concentrations have been associated with increasing likelihood of developing OHSS and there is some evidence to suggest that coasting can significantly reduce the incidence of severe OHSS by withdrawing exogenous gonadotropins until the patient&#x02019;s serum estradiol concentration falls to a safer level before hCG trigger [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Ovarian stimulation in IVF cycle also results in supraphysiological concentrations of progesterone and estrogen during the luteal phase. In recent years, two studies reported that the addition of aromatase inhibitor for high-risk OHSS patients during the luteal phase of stimulated donor IVF cycles significantly reduces serum estradiol levels and impacts corpus luteum function [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. In animal studies, low doses of RU-486, an anti-progestin, caused alterations in ovarian weight, peritoneal capillary permeability, and the volume of ascites. These were associated with a visible decrease in OHSS in model rats [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. This raises questions about the relationship with ovarian steroid hormone levels and OHSS during the luteal phase. Whether the suppression of ovarian steroid hormone productions and promotion of regression of the corpus luteum during the luteal phase after oocyte retrieval in patients at high risk of OHSS can decrease the incidence and severity of OHSS has yet to be verified.</p><p>Gonadotropin-releasing hormone antagonist (GnRH-ant) has seen widespread use in the past two decades in in vitro fertilization-embryo transfer (IVF-ET), where it prevents the surge in luteinizing hormone (LH) surge and suppression of estradiol levels in follicular phase [<xref ref-type="bibr" rid="CR12">12</xref>]. The use of GnRH antagonist protocol in IVF has been found to be associated with a significantly lower incidence of OHSS and E<sub>2</sub> concentrations on the day of hCG administration than on the day of treatments compared with GnRH agonists [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. In recent years, luteal phase GnRH-ant administration has appeared to prevent patient hospitalization for patients with established severe early OHSS and results in quick regression of the syndrome on an outpatient basis [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. However, the LH values fall rapidly after oocyte retrieval in the luteal phase of the stimulated cycles, making it unclear whether exogenous suppression of LH levels during the luteal phase is necessary? Can it really block pathogenesis of OHSS and reduce the risk of severe OHSS? For above reasons, the specific aim of this study was sought to investigate the relationship between administration of steroidal ovarian suppression in the luteal phase and OHSS.</p><p>In the present study, aromatase inhibitor, anti-progestin, and GnRH-ant were given to patients at high risk of OHSS in luteal phase after oocyte retrieval. The efficacy of intervention during the luteal phase after oocyte retrieval for the prevention and treatment of early-onset OHSS in patients undergoing embryo cryopreservation was examined.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Patient population</title><p>This is a prospective, observational, cohort study performed at the Reproductive Medical Center of the Renmin Hospital of Wuhan University in China from January 2010 to December 2013. A total of 281 women at high risk of OHSS among 4735 consecutive patients under 38&#x000a0;years old planning to undergo their first IVF treatment were included in this study. All participating patients met at least one of the following criteria: (1) Number of retrieved oocytes&#x02009;&#x02265;&#x02009;20; (2) mean number of follicles with a diameter greater than 14&#x000a0;mm&#x02009;&#x02265;&#x02009;20; (3) serum E<sub>2</sub> concentrations reached&#x02009;&#x02265;&#x02009;8 000&#x000a0;pg/ml; (4) on the day of oocyte retrieval, the ovarian diameter was&#x02009;&#x0003e;&#x02009;10&#x000a0;cm; and\presentation of obviously symptoms of OHSS on the day of aspiration. The couples were given counseling regarding the high risks and symptoms of OHSS and all agreed to cancel fresh embryo transfer. Each patient was allowed to participate in the study only once. We strictly obeyed the Declaration of Helsinki for Medical Research involving human subjects during the project and written consent was obtained from all subjects. The protocol was approved by the Ethical Research Committee of Renmin Hospital of Wuhan University (No.WHR09125).</p></sec><sec id="Sec4"><title>Stimulation protocol and IVF procedure</title><p>In all the cases, a long mid-luteal GnRH agonist protocol was adopted for superovulation. Down-regulation was carried out using daily GnRH agonist (triptorelin, s.c.0.1&#x000a0;mg, Ferring, Pharmaceuticals, Kiel, Germany) beginning on day 21 of the previous cycle, as confirmed by a blood test. After 2&#x02013;3 weeks of down-regulation, confirmed by a blood test and ultrasound, gonadotropin (Gonal-F, im, 75 IU or 450 IU, Merck-Serono, Aubonne, Switzerland) was administered intramuscularly at 112.5&#x02013;225&#x000a0;IU/day starting on cycle days 5&#x02013;8 of stimulation. Gn dose was adjusted according to ovarian response. All patients were monitored using transvaginal ultrasound and serum ovarian steroid hormone concentrations during superovulation. Final oocyte maturation was triggered when at least three follicles&#x02009;&#x02265;&#x02009;17&#x000a0;mm were present on ultrasound, with administration of 6000&#x02013;8000&#x000a0;IU hCG injection (hCG, 1000&#x000a0;IU, Lizhu Pharmaceuticals, Zhuhai, China). Transvaginal oocyte aspiration was performed 36&#x000a0;h later by ultrasound-guided follicle puncture. All embryos were cryopreserved on day 3 after IVF due to high risk of OHSS and/or severe early-developing OHSS.</p></sec><sec id="Sec5"><title>Grouping and intervention</title><p>281 consecutive high-risk patients received intra-venous fluid administration after the day of oocyte retrieval and were divided into a treatment group (<italic>n</italic>&#x02009;=&#x02009;161) and control group (<italic>n</italic>&#x02009;=&#x02009;120). The patients in the treatment group were informed of treatment options: letrozole group: (<italic>n</italic>&#x02009;=&#x02009;43) received aromatase inhibitors letrozole tab (2.5&#x000a0;mg, bid, Femara; Novartis, Barcelona, Spain) per day for 5 consecutive days beginning on the day after oocyte retrieval. Mifepristone group (<italic>n</italic>&#x02009;=&#x02009;51): received mifepristone tab (25&#x000a0;mg, bid; Zizhu Pharmaceuticals, Beijin, China) per day for 3 consecutive days beginning on the day after oocyte retrieval. GnRH-antagonist group (<italic>n</italic>&#x02009;=&#x02009;39): received cetrotide (0.25&#x000a0;mg, qd, subcutaneous, Merck-Serono, Halle, Germany) per day for 5 consecutive days beginning on the day after oocyte retrieval. Three-drug combinations (Combinations) group (<italic>n</italic>&#x02009;=&#x02009;28): took letrozole, mifepristone and cetrotide together at the same time. The control group (<italic>n</italic>&#x02009;=&#x02009;120): received no special medication and was similar to the study group with regard to basal characteristics and ART stimulation parameters. In addition, 4454 patients under 38&#x000a0;years old planning to undergo their first IVF treatment as the non-high risk group were included and data on basal parameters were analyzed.</p></sec><sec id="Sec6"><title>Steroid hormone assay</title><p>Blood was withdrawn from patients in all groups on days 2, 5, and 8 after oocyte retrieval. Serum E<sub>2</sub>, LH, and progesterone (P<sub>4</sub>) levels were measured using an Immulite analyzer and commercially available kits (DPC, Los Angeles, CA, U.S.). Analytical sensitivity were 15&#x000a0;pg/ml for E<sub>2</sub>, 0.2&#x000a0;ng/ml for P<sub>4</sub> and 0.1 mIU/ml for LH. Intra- and inter-assay precisions at the concentrations of most relevance to the current study (expressed as coefficients of variation) were 6.1 and 6.3&#x000a0;% for E<sub>2</sub>, 7.8 and 10.1&#x000a0;% for P<sub>4</sub>, and 5.8 and 8.2&#x000a0;% for LH, respectively.</p></sec><sec id="Sec7"><title>Monitoring of patients</title><p>Monitoring of patients consisted of general information, symptoms, complications during the hospitalization (ovarian torsion, thromboembolic events), embryonic condition, body mass index (BMI), abdomen circumference, ascites, and pleural effusion, urine output, days of luteal phase, whether paracentesis had taken place, and the amount of albumin (Alb) transfused were monitored and recorded. Biochemical values such as hematocrit, white blood cell count, Alb levels, blood urea nitrogen, creatinine, liver enzymes, prothrombin time, and partial thrombin time were measured when necessary. Patients were followed until menstruation.</p><p>The diagnostic criteria for OHSS were according to Golan&#x02019;s classification [<xref ref-type="bibr" rid="CR20">20</xref>]. Patients with mild OHSS presented with symptoms of mild abdominal distension and discomfort, possibly accompanied by nausea, vomiting and diarrhea, and an ovarian diameter of &#x02264;5&#x000a0;cm. Moderate OHSS was defined as an aggravation of the aforementioned symptoms, associated with a weight gain of &#x0003e;4.5&#x000a0;kg, ascites identified by ultrasound examination and an ovarian diameter of 5&#x02013;10&#x000a0;cm. Severe OHSS was defined as marked ascites and/or hydrothorax, hematocrit&#x02009;&#x0003e;&#x02009;45&#x000a0;%, white blood cell count (WBC) &#x0003e;15,000/mm<sup>3</sup>, dyspnea, oliguria or abnormal liver function tests, and large ovaries (&#x0003e;10&#x000a0;cm maximum diameter).</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>Statistical analysis was performed using SPSS 12.0 statistical software (Chicago, IL, U.S.) according to the intention to treat principle. All analyses of significance were two-sided and tested at the 5&#x000a0;% level. <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant. Continuous variables were tested if they presented normal distribution using the F-test. The results of the multiple groups were compared using the ANOVA and the comparison among groups was performed with an LSD test. Qualitative variables were assessed with the chi-squared method and Yate&#x02019;s correction. In the present study, a serum P<sub>4</sub> level over 60&#x000a0;ng/ml was taken to be 60&#x000a0;ng/ml exactly, because the samples were not diluted any further.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>General information</title><p>In this patient cohort, the five high-risk groups were compared for age, BMI, number of cases of polycystic ovary syndrome (PCOS), duration of infertility, baseline follicle-stimulating hormone (FSH), E<sub>2</sub>, duration of Gn stimulation, and Gn dose received by the patients. No significant differences were observed for any of the parameters (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The mean E<sub>2</sub> concentration on the day of HCG administration, number of follicles with a diameter &#x02265;14&#x000a0;mm, number of oocytes retrieved, fertilization rate, cleavage rate, and quality embryo rate were also comparable among the five high-risk groups. But the mean E<sub>2</sub> concentration on the day of HCG administration, number of follicles with a diameter &#x02265;14&#x000a0;mm, number of oocytes retrieved, the number of usable embryos was significant decreased in non high-risk group compare with each high-risk subgroup (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>General information of OHSS high-risk and non high-risk groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"/><th colspan="5">OHSS high-risk groups (<italic>n</italic>&#x02009;=&#x02009;281)</th><th rowspan="2">OHSS non high-risk group</th></tr><tr><th>Letrozole group</th><th>Mifepristone group</th><th>GnRH-ant group</th><th>Three-drug group</th><th>Control group</th></tr><tr><th>(<italic>n</italic>&#x02009;=&#x02009;43)</th><th>(<italic>n</italic>&#x02009;=&#x02009;51)</th><th>(<italic>n</italic>&#x02009;=&#x02009;39)</th><th>(<italic>n</italic>&#x02009;=&#x02009;28)</th><th>(<italic>n</italic>&#x02009;=&#x02009;120)</th><th>(<italic>n</italic>&#x02009;=&#x02009;4454)</th></tr></thead><tbody><tr><td>Age (year)</td><td>30.6&#x02009;&#x000b1;&#x02009;3.5</td><td>29.7&#x02009;&#x000b1;&#x02009;4.1</td><td>29.9&#x02009;&#x000b1;&#x02009;4.2</td><td>30.2&#x02009;&#x000b1;&#x02009;3.8</td><td>30.1&#x02009;&#x000b1;&#x02009;4.0</td><td>30.9&#x02009;&#x000b1;&#x02009;3.9</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>21.8&#x02009;&#x000b1;&#x02009;3.3</td><td>21.5&#x02009;&#x000b1;&#x02009;4.3</td><td>21.7&#x02009;&#x000b1;&#x02009;3.0</td><td>21.2&#x02009;&#x000b1;&#x02009;3.5</td><td>21.4&#x02009;&#x000b1;&#x02009;2.9</td><td>21.3&#x02009;&#x000b1;&#x02009;3.6</td></tr><tr><td>PCOS (n)</td><td>7 (16.3&#x000a0;%)</td><td>8 (15.7&#x000a0;%)</td><td>5 (12.8&#x000a0;%)</td><td>4 (14.3&#x000a0;%)</td><td>18 (15.0&#x000a0;%)</td><td>142 (3.2&#x000a0;%)</td></tr><tr><td>Duration of infertility (year)</td><td>4.9&#x02009;&#x000b1;&#x02009;2.5</td><td>4.7&#x02009;&#x000b1;&#x02009;2.8</td><td>4.6&#x02009;&#x000b1;&#x02009;3.2</td><td>4.4&#x02009;&#x000b1;&#x02009;3.1</td><td>4.3&#x02009;&#x000b1;&#x02009;3.5</td><td>4.8&#x02009;&#x000b1;&#x02009;3.6</td></tr><tr><td>Baseline FSH (IU/L)</td><td>5.6&#x02009;&#x000b1;&#x02009;1.8</td><td>5.3&#x02009;&#x000b1;&#x02009;1.7</td><td>5.9&#x02009;&#x000b1;&#x02009;1.5</td><td>5.8&#x02009;&#x000b1;&#x02009;1.7</td><td>6.1&#x02009;&#x000b1;&#x02009;1.6</td><td>6.3&#x02009;&#x000b1;&#x02009;1.5</td></tr><tr><td>Baseline E<sub>2</sub> (pg/ml)</td><td>51.2&#x02009;&#x000b1;&#x02009;19.4</td><td>49.3&#x02009;&#x000b1;&#x02009;17.6</td><td>50.9&#x02009;&#x000b1;&#x02009;17.8</td><td>47.4&#x02009;&#x000b1;&#x02009;16.5</td><td>48.2&#x02009;&#x000b1;&#x02009;18.2</td><td>46.6&#x02009;&#x000b1;&#x02009;18.3</td></tr><tr><td>Duration of Gn (days)</td><td>11.1&#x02009;&#x000b1;&#x02009;2.0</td><td>11.2&#x02009;&#x000b1;&#x02009;1.9</td><td>10.9&#x02009;&#x000b1;&#x02009;1.6</td><td>11.5&#x02009;&#x000b1;&#x02009;1.8</td><td>11.3&#x02009;&#x000b1;&#x02009;2.1</td><td>11.2&#x02009;&#x000b1;&#x02009;2.2</td></tr><tr><td>Total Gn ampoules (75&#x000a0;IU)</td><td>24.7&#x02009;&#x000b1;&#x02009;6.3</td><td>24.9&#x02009;&#x000b1;&#x02009;6.8</td><td>25.3&#x02009;&#x000b1;&#x02009;6.5</td><td>25.7&#x02009;&#x000b1;&#x02009;6.6</td><td>25.2&#x02009;&#x000b1;&#x02009;6.4</td><td>28.7&#x02009;&#x000b1;&#x02009;9.8</td></tr></tbody></table><table-wrap-foot><p>Values are means&#x02009;&#x000b1;&#x02009;SD. Values in parentheses are percentages</p><p>
<italic>BMI</italic> body mass index, <italic>PCOS</italic> polycystic ovary syndrome <italic>FSH</italic> follical stimulation hormone, <italic>E</italic>
<sub><italic>2</italic></sub> estradiol, <italic>Gn</italic> gonadotropin</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Treatment and in vitro fertilization parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"/><th colspan="5">OHSS high-risk groups (<italic>n</italic>&#x02009;=&#x02009;281)</th><th rowspan="2">OHSS non high-risk group</th></tr><tr><th>Letrozole group</th><th>Mifepristone group</th><th>GnRH-ant group</th><th>Three-drug group</th><th>Control group</th></tr><tr><th>(<italic>n</italic>&#x02009;=&#x02009;43)</th><th>(<italic>n</italic>&#x02009;=&#x02009;51)</th><th>(<italic>n</italic>&#x02009;=&#x02009;39)</th><th>(<italic>n</italic>&#x02009;=&#x02009;28)</th><th>(<italic>n</italic>&#x02009;=&#x02009;120)</th><th>(<italic>n</italic>&#x02009;=&#x02009;4454)</th></tr></thead><tbody><tr><td>Estradiol (pg/ml)<sup>a</sup>
</td><td>7871.8&#x02009;&#x000b1;&#x02009;2527.2</td><td>8012.4&#x02009;&#x000b1;&#x02009;2252.6</td><td>8449.3&#x02009;&#x000b1;&#x02009;2391.8</td><td>8225.6&#x02009;&#x000b1;&#x02009;2734.3</td><td>8437.1&#x02009;&#x000b1;&#x02009;2885.9</td><td>2825.6&#x02009;&#x000b1;&#x02009;1754.2*</td></tr><tr><td>No. follicles with diameter &#x0003e;</td><td>29.2&#x02009;&#x000b1;&#x02009;8.4</td><td>28.3&#x02009;&#x000b1;&#x02009;7.6</td><td>30.6&#x02009;&#x000b1;&#x02009;7.3</td><td>30.3&#x02009;&#x000b1;&#x02009;8.1</td><td>31.1&#x02009;&#x000b1;&#x02009;6.9</td><td>16.5&#x02009;&#x000b1;&#x02009;6.3*</td></tr><tr><td>14&#x000a0;mm</td><td/><td/><td/><td/><td/><td/></tr><tr><td>No. oocytes retrieved</td><td>27.4&#x02009;&#x000b1;&#x02009;6.6</td><td>25.1&#x02009;&#x000b1;&#x02009;5.7</td><td>27.3&#x02009;&#x000b1;&#x02009;5.9</td><td>26.8&#x02009;&#x000b1;&#x02009;6.2</td><td>26.4&#x02009;&#x000b1;&#x02009;6.1</td><td>12.2&#x02009;&#x000b1;&#x02009;6.4*</td></tr><tr><td>Fertilization rate (%)</td><td>82.8</td><td>80.6</td><td>81.1</td><td>79.7</td><td>83.2</td><td>79.5</td></tr><tr><td>Cleavage rate (%)</td><td>98.3</td><td>97.5</td><td>98.3</td><td>97.1</td><td>97.9</td><td>98.2</td></tr><tr><td>Quality embryo rate (%)</td><td>62.7</td><td>60.8</td><td>63.1</td><td>59.7</td><td>61.9</td><td>63.6</td></tr><tr><td>No. usable embryos (n)</td><td>13.2&#x02009;&#x000b1;&#x02009;5.8</td><td>12.4&#x02009;&#x000b1;&#x02009;4.9</td><td>13.6&#x02009;&#x000b1;&#x02009;5.1</td><td>12.5&#x02009;&#x000b1;&#x02009;5.6</td><td>13.7&#x02009;&#x000b1;&#x02009;6.3</td><td>6.2&#x02009;&#x000b1;&#x02009;2.7*</td></tr></tbody></table><table-wrap-foot><p>Values are means&#x02009;&#x000b1;&#x02009;SD. Values in parentheses are percentages</p><p>*<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 compare with each high-risk subgroup</p><p>
<sup>a</sup>Serum oestradiol concentration on the day of human chorionic gonadotrophin (HCG) administration</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Serum steroid hormone levels</title><p>The serum E<sub>2</sub>, LH, and P<sub>4</sub> concentrations were measured on days 2, 5, and 8 after oocyte retrieval. The results showed that, on days 2 and 5, the serum E<sub>2</sub> levels tended to increase in five high-risk groups, but on day 8, there was an apparent gradual decrease (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>). In five groups, there were no significant differences in serum E<sub>2</sub> levels on days 2, 5, and 8 after oocyte retrieval within the cetrotide group, mifepristone group, and control group (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05), apart from a significantly lower E<sub>2</sub> levels in the letrozole group and three-drug group (<italic>P&#x02009;&#x0003c;</italic>&#x02009;0.001). The datasets of serum E<sub>2</sub> levels were analyzed further on days 2, 5, and 8 in the control group. Serum E<sub>2</sub> levels were significantly higher in the moderate/severe OHSS subgroup than in the mild OHSS subgroup, and the decline in E<sub>2</sub> level was significantly slower (<italic>P&#x02009;&#x0003c;</italic>&#x02009;0.05) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>
<bold>a</bold>, serum estradiol level; <bold>b</bold>, serum luteinizing hormone level; <bold>c</bold>, serum P<sub>4</sub> level. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, vs. control group</p></caption><graphic xlink:href="13048_2015_190_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Control group <bold>a</bold>: mild OHSS patients; Control group <bold>b</bold>: moderate/ severe OHSS patients. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, vs. control group B</p></caption><graphic xlink:href="13048_2015_190_Fig2_HTML" id="MO2"/></fig></p><p>Serum LH levels showed that at much lower levels on days 2, 5, and 8 (LH&#x02009;&#x0003c;&#x02009;0.1&#x000a0;IU/L) in five groups and the fluctuation was small (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). There were no significantly difference of serum LH concentration on days 2, 5, and 8 after oocyte retrieval in five groups (<italic>P&#x02009;&#x0003e;</italic>&#x02009;0.05). The serum P<sub>4</sub> levels were found to be &#x0003e;60&#x000a0;ng/ml on days 2 and 5, but a decrease was observed on day 8 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>). There were no significant differences in serum P<sub>4</sub> levels on day 8 in any of the five high-risk groups (<italic>P&#x02009;&#x0003e;</italic>&#x02009;0.05), even though the serum P<sub>4</sub> values on days 2 and 5 unable to be compare accurately (because that the Clinical Laboratory of Renmin Hospital did not dilute serum samples for further testing when the serum P<sub>4</sub> concentration was higher than 60&#x000a0;ng/ml). There were no significant differences in serum LH and P<sub>4</sub> levels in any of the five groups, but serum E<sub>2</sub> levels were significantly lower in the letrozole and three-drug groups than in the other groups.</p></sec><sec id="Sec12"><title>Clinical outcomes</title><p>All 281 patients were followed up until their next menses. The clinical outcomes of patients in five groups are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. The proportion of patients at high risk for OHSS who developed moderate early OHSS was 27.9&#x000a0;% (12/43), 29.4&#x000a0;% (15/51), 33.3&#x000a0;% (13/39), 25.0&#x000a0;% (8/28), and 27.5&#x000a0;% (33/120) in the letrozole group, mifepristone group, GnRH-ant group, three-drug group, and control group, respectively. The incidence of severe early OHSS in patients was 16.3&#x000a0;% (7/43), 19.6&#x000a0;% (10/51), 18.0&#x000a0;% (7/39), 17.9&#x000a0;% (5/28), and 18.3&#x000a0;% (22/120) in the letrozole group, mifepristone group, GnRH-ant group, three-drug group, and control group, respectively. The incidence of high risk of OHSS in this IVF population was 5.93&#x000a0;% (281/4735), the total incidence of severe early OHSS was 1.18&#x000a0;% (55/4735) while 51 out of 55 cases happened in risk patients.<table-wrap id="Tab3"><label>Table 3</label><caption><p>OHSS outcomes of high-risk treatment and control groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"/><th colspan="4">Treatment groups (<italic>n</italic>&#x02009;=&#x02009;161)</th><th rowspan="2">Control group</th></tr><tr><th>Letrozole group</th><th>Mifepristone group</th><th>GnRH-ant group</th><th>Three-drug group</th></tr><tr><th>(<italic>n</italic>&#x02009;=&#x02009;43)</th><th>(<italic>n</italic>&#x02009;=&#x02009;51)</th><th>(<italic>n</italic>&#x02009;=&#x02009;39)</th><th>(<italic>n</italic>&#x02009;=&#x02009;28)</th><th>(<italic>n</italic>&#x02009;=&#x02009;120)</th></tr></thead><tbody><tr><td>Paracentesis (n)</td><td>7 (16.3&#x000a0;%)</td><td>9 (17.7&#x000a0;%)</td><td>7 (17.9&#x000a0;%)</td><td>4 (14.3&#x000a0;%)</td><td>21 (19.2&#x000a0;%)</td></tr><tr><td>Length of hospital stay(days)</td><td>7.0&#x02009;&#x000b1;&#x02009;2.9</td><td>7.4&#x02009;&#x000b1;&#x02009;2.5</td><td>7.1&#x02009;&#x000b1;&#x02009;2.8</td><td>6.8&#x02009;&#x000b1;&#x02009;2.1</td><td>7.3&#x02009;&#x000b1;&#x02009;2.7</td></tr><tr><td>Severity of OHSS</td><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Mild (n)</td><td>24 (55.8&#x000a0;%)</td><td>26 (51.0&#x000a0;%)</td><td>19 (48.7&#x000a0;%)</td><td>15 (53.6&#x000a0;%)</td><td>65 (54.2&#x000a0;%)</td></tr><tr><td>&#x02003;Moderate (n)</td><td>12 (27.9&#x000a0;%)</td><td>15 (29.4&#x000a0;%)</td><td>13 (33.3&#x000a0;%)</td><td>8 (25.0&#x000a0;%)</td><td>33 (27.5&#x000a0;%)</td></tr><tr><td>&#x02003;Severe (n)</td><td>7 (16.3&#x000a0;%)</td><td>10 (19.6&#x000a0;%)</td><td>7 (18.0&#x000a0;%)</td><td>5 (17.9&#x000a0;%)</td><td>22 (18.3&#x000a0;%)</td></tr><tr><td>Complications (n)</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1<sup>b</sup>
</td></tr><tr><td>Luteal phase(days)<sup>a</sup>
</td><td>10.9&#x02009;&#x000b1;&#x02009;2.6</td><td>10.5&#x02009;&#x000b1;&#x02009;1.9</td><td>10.7&#x02009;&#x000b1;&#x02009;2.4</td><td>10.4&#x02009;&#x000b1;&#x02009;2.3</td><td>11.2&#x02009;&#x000b1;&#x02009;3.1</td></tr></tbody></table><table-wrap-foot><p>Values are means&#x02009;&#x000b1;&#x02009;SD unless otherwise stated. Values in parentheses are percentages. <italic>OHSS</italic> ovarian hyperstimulation syndrome, <italic>NS</italic> not statistically significant</p><p>
<sup>a</sup>Luteal phase&#x02009;=&#x02009;interval between oocyte retrieval and next menstrual cycle</p><p>
<sup>b</sup>One patient experienced ovarian torsion</p></table-wrap-foot></table-wrap></p><p>The duration of hospitalization was 7.0&#x02009;&#x000b1;&#x02009;2.9&#x000a0;days in the letrozole group, 7.4&#x02009;&#x000b1;&#x02009;2.5&#x000a0;days in the mifepristone group, 7.1&#x02009;&#x000b1;&#x02009;2.8&#x000a0;days in the GnRH-ant group, 6.8&#x02009;&#x000b1;&#x02009;2.1&#x000a0;days in the three-drug group, and 7.3&#x02009;&#x000b1;&#x02009;2.7&#x000a0;days in the control group. The incidence of moderate or severe OHSS and the duration of hospitalization was not significantly lower than in the control group in any of the treatment subgroups (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05). Paracentesis was performed for drainage of abdominal fluid in severe OHSS patients. In the letrozole group, 16.3&#x000a0;% (7/43) of the patients underwent paracentesis, 17.7&#x000a0;% (9/51) in the mifepristone group, 17.9&#x000a0;% (7/39) in the GnRH-ant group, and 14.3&#x000a0;% (4/28) in the three-drug group. These values are statistically similar to the 17.5&#x000a0;% (21/120) in the control group (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05).</p><p>The duration of the luteal phase (interval between oocyte retrieval and next menstrual cycle) was 10.9&#x02009;&#x000b1;&#x02009;2.6&#x000a0;days in the letrozole group, 10.5&#x02009;&#x000b1;&#x02009;1.9&#x000a0;days in the mifepristone group, 10.7&#x02009;&#x000b1;&#x02009;2.4&#x000a0;days in the GnRH-ant group, 10.4&#x02009;&#x000b1;&#x02009;2.3&#x000a0;days in the three-drug group, and 11.2&#x02009;&#x000b1;&#x02009;3.1&#x000a0;days in the control group. These durations were comparable (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05). Notably, there were no serious adverse complications during hospitalization for OHSS observed in treatment group, but there was one case of ovarian torsion in the control group.</p></sec></sec><sec id="Sec13" sec-type="discussion"><title>Discussion</title><p>To the best of our knowledge, this is the first study to investigate the incidence of early-onset OHSS in high-risk patients using different types of steroidogenic suppression during the luteal phase. In the present study, the severe early OHSS occurred in the rate of 1.18&#x000a0;% for all cycles, and the incidence in high-risk patients nearly approached to 20&#x000a0;%, which is markedly higher than common IVF patients. This results demonstrated that the preferred management for the patients with potential OHSS included early recognition of risk factors and timely management. Ovulation induction should be highly individualized, carefully monitored, and use the minimum dose and duration of gonadotropin therapy necessary to achieve the therapeutic goal. Primary preventative measures of OHSS in follicular phase included mild ovarian stimulation, coasting, GnRH-antagonist protocol, cancel cycle, withholding HCG or GnRH agonist trigger. If the ovaries are overstimulated despite meticulous attention to the above recommendations, secondary measures should be instituted to prevent the occurrence of severe OHSS or to minimize its severity.</p><p>Ovarian stimulation in IVF cycle results in luteal supraphysiological steroid concentrations especially for OHSS high-risk patients [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. The current study showed changes in serum luteal steroid concentrations on different days in patients at high risk of OHSS. Results were consistent with those of previous studies. The luteal E<sub>2</sub> concentration in superovulation cycle showed the same fluctuation as in natural cycles. However, the absolute value of E<sub>2</sub> was visibly higher than its natural counterparts. Serum E<sub>2</sub> levels of high-risk control group with moderate/severe OHSS were significantly higher than those of patients with mild OHSS in day 2 and day 5, and the decline in E<sub>2</sub> on day 8 in the former subgroup was also slower than that of the latter subgroup. This suggests to us that serum estrogen level is, to a certain degree, associated with severity of OHSS, and that caution should be exercised regarding embryo transfer in patients who show a relatively high estrogen level on day 2 or day 5 after oocyte retrieval. Moreover, P<sub>4</sub> secretion was here found to very exuberant, but the peak appeared earlier, and the average duration of the luteal phase is 11.3&#x02009;&#x000b1;&#x02009;3.0&#x000a0;days which is shorter than nature cycle. The results verified concept of luteolytic effect after GnRH agonist and superovulation. Furthermore, LH decreased to a very low level after aspiration as same as nature cycle. According the secretion of steroid hormone in luteal phase, to minimize the risk of severe complications, secondary preventative measures are applied by different steroidogenic suppression therapy during luteal phase for OHSS high-risk patients.</p><p>A close relationship was observed between high levels of serum estradiol and the incidence of OHSS, as reported previously by others [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. After superovulation, patients at high risk of OHSS have relatively high estradiol levels not only during the follicular phase but also during the luteal phase. Letrozole is a highly specific non-steroidal, aromatase-selective inhibitor that can block the conversion of androgens to estrogen [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. Letrozole at doses of 1&#x02013;5&#x000a0;mg/day can inhibit aromatase activity by 97&#x02013;99&#x000a0;% [<xref ref-type="bibr" rid="CR31">31</xref>]. In the present work, results showed that E<sub>2</sub> levels decreased markedly on different luteal days but there was no difference in progesterone levels after letrozole administration. This is in consistent with findings reported by Fatemi et al. and Garcia-Velasco et al. [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Unlike the Garcia-Velasco study, we found no different in serum LH levels. Further follow-up examination did not reveal any statistically significant difference in the rates of severe OHSS, duration of the luteal phase and hospitalization period between the letrozole group and control group. The high estradiol levels observed during the luteal phase may have been caused by exuberant secretion from multiple corpus luteum after superovulation in follicular phase. Exogenous aromatase inhibitor therapy during the luteal phase cannot completely blocking OHSS in either pathogenesis or pathophysiology.</p><p>Previous observations reported that elevated plasma concentrations of progesterone, in addition to estradiol, during the clinical phase of OHSS [<xref ref-type="bibr" rid="CR32">32</xref>]. In clinical manifestation, the peak days of early OHSS coincide with maximum secretion by the corpus luteum and instantly relieves after menstruation. Severe OHSS is frequently associated with pregnancy, which suggests that progesterone is involved in OHSS pathophysiology. Mifepristone, a progesterone antagonist, is a synthetic steroid hormone that binds to the progesterone receptor. It has been predominantly and successfully used in the termination of early pregnancies [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Ujioka et al. reported that low doses of RU-486 (&#x0003c;10&#x000a0;mg/kg) may decrease ovarian and peritoneal capillary permeability in hyperstimulated rats, probably through the anti- glucocorticoid effect and antiprogestational activity and modulation of vascular endothelial growth factor (VEGF) and different cytokine effects [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. In a recent study, Yung et al. found out that RU-486 represses LHCGR expression and LH/hCG signaling in cultured luteinized human mural granulosa cells [<xref ref-type="bibr" rid="CR35">35</xref>]. In the current study, mifepristone was first administered during the early luteal phase for patients at high risk of OHSS who had cryopreserved all embryos. The current observation shows that steroid levels, severe OHSS rates and paracentesis rate are not significantly different in the mifepristone and control groups.</p><p>LH plays a crucial role in the steroidogenic activity of the corpus luteum that takes place during the luteal phase [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. OHSS is usually observed several days after hCG trigger, and its severe form is frequently associated with pregnancy or hCG supperly during the luteal phase [<xref ref-type="bibr" rid="CR20">20</xref>]. LH and hCG share the same &#x003b1;-subunit and 81&#x000a0;% of the amino-acid residues of the &#x003b2;-subunit. They also bind to the same receptor, the LH/hCG receptor. It has been reported that luteal GnRH antagonist administration in patients with established severe early OHSS appears to prevent the need for patient hospitalization and causes quick regression of the syndrome on an outpatient basis [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. Mais et al. found that administration of GnRH antagonist during the mid-luteal phase in natural menstrual cycles could induce luteolysis by reducing pulsatile gonadotrophin stimulation. This caused a rapid decline in serum estradiol and progesterone concentrations and the onset of menstrual bleeding [<xref ref-type="bibr" rid="CR38">38</xref>]. The present study, on the contrary, showed that the luteal-phase steroid concentration is physiologically comparable to that of the control group and the incidence of severe OHSS was roughly the same in the cetrotide group and control group. These results may be explained by several factors. First, luteal phase LH secretion is profoundly suppressed by the pituitary via negative feedback actions at the level of the hypothalamic-pituitary axis because of luteal supraphysiological concentrations of progesterone and estradiol [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. Cetrotide&#x02019;s anti-steroid activity is weak on deeply suppressed LH levels. However, even though it has been demonstrated that a few GnRH receptors are expressed in the ovary, low-dose GnRH-ant exerts only a slight an antagonistic effect there [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p>In our study, letrozole, mifepristone, and cetrotide were co-administered and synergistic effects were observed. We found that luteal steroidogenic suppression even by three-drug combinations can&#x02019;t block the ongoing process of OHSS compared with control group. Consideration should be given to the possibility that the overstimulated ovaries, provoked by exogenous hCG injection, leads to the ovarian release of vasoactive-angiogenic substances increasing the vascular permeability and the full blown syndrome as a consequence. Anti-steroidogenic thoerpy during the luteal phase can not fundamentally block the effect of hCG and pathophysiology of OHSS.</p><p>The major limitation in this pilot cohort study was the lack of information regarding the VEGF, interleukins and rennin angiotensinogen system which have been implicated in the pathogenesis of OHSS in the serum and ascites of these patients. This study is also limited by its sample size of subgroup and non-randomized design. No experiments were performed to compare the effects of these drugs at different dosages, the timing or duration of treatment, or different types of anti-steroidogenic medicine.</p></sec><sec id="Sec14" sec-type="conclusion"><title>Conclusions</title><p>These data demonstrate that, at present, there is no difference in the rate of severe OHSS rate in patients at high risk of OHSS, regardless of the type of luteal steroidogenic suppression given. Currently, the etiology of OHSS is not sufficiently known and therapy remains experimental. In patients at high risk of OHSS, once triggered by hCG, OHSS induces a cascade of effects. Steroidogenic suppression during the luteal phase does not achieve a satisfactory outcome. The key to the primary prevention of OHSS during control ovarian stimulation is recognition of risk factors and individualization of the ovarian stimulation protocol. Further studies and more patients are needed to determine how feasible it is to completely eliminate OHSS.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BMI</term><def><p>Body mass index</p></def></def-item><def-item><term>E<sub>2</sub></term><def><p>Estradiol</p></def></def-item><def-item><term>FSH</term><def><p>Follicle-stimulating hormone</p></def></def-item><def-item><term>GnRH-ant</term><def><p>Gonadotropin-releasing hormone antagonist</p></def></def-item><def-item><term>hCG</term><def><p>Human chorionic gonadotrophin</p></def></def-item><def-item><term>IVF-ET</term><def><p>In vitro fertilization-embryo transfer</p></def></def-item><def-item><term>LH</term><def><p>Luteinizing hormone</p></def></def-item><def-item><term>OHSS</term><def><p>Ovarian hyperstimulation syndrome</p></def></def-item><def-item><term>P<sub>4</sub></term><def><p>Progesterone</p></def></def-item><def-item><term>PCOS</term><def><p>Polycystic ovary syndrome</p></def></def-item><def-item><term>VEGF</term><def><p>Vascular endothelial growth factor</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interest.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>YW, JY and WX: Conceived and designed the experiments. YW, QX, JL, WY performed the experiments. YW and GW analyzed the datas. JL contributed reagents/ materials/analysis tools. YW wrote the paper. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was in part supported by by the National Nature Science Foundation of China Grant (31000581), the Major State Basic Research Development Program (No.2011CB944404) and family planning fund of Hubei province of China, project # JS-20130012. We acknowledge the Infertility staff of Renmin Hospital of Wuhan university and the patients who kindly cooperated with the researchers.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aboulghar</surname><given-names>MA</given-names></name><name><surname>Mansour</surname><given-names>RT</given-names></name></person-group><article-title>Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures</article-title><source>Hum Reprod Update</source><year>2003</year><volume>9</volume><fpage>275</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1093/humupd/dmg018</pub-id><pub-id pub-id-type="pmid">12859048</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamath</surname><given-names>MS</given-names></name><name><surname>Joshi</surname><given-names>A</given-names></name><name><surname>Kamath</surname><given-names>AM</given-names></name><name><surname>Aleyamma</surname><given-names>T</given-names></name></person-group><article-title>Management of severe ovarian hyperstimulation syndrome with thawed plasma</article-title><source>J Hum Reprod Sci</source><year>2013</year><volume>6</volume><fpage>82</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.4103/0974-1208.112390</pub-id><pub-id pub-id-type="pmid">23869160</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egbase</surname><given-names>PE</given-names></name></person-group><article-title>Severe OHSS: how many cases are preventable?</article-title><source>Hum Reprod</source><year>2000</year><volume>15</volume><fpage>8</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1093/humrep/15.1.8</pub-id><pub-id pub-id-type="pmid">10611179</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papanikolaou</surname><given-names>EG</given-names></name><name><surname>Pozzobon</surname><given-names>C</given-names></name><name><surname>Kolibianakis</surname><given-names>EM</given-names></name><name><surname>Camus</surname><given-names>M</given-names></name><name><surname>Tournaye</surname><given-names>H</given-names></name><name><surname>Fatemi</surname><given-names>HM</given-names></name><name><surname>Van Steirteghem</surname><given-names>A</given-names></name><name><surname>Devroey</surname><given-names>P</given-names></name></person-group><article-title>Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles</article-title><source>Fertil Steril</source><year>2006</year><volume>85</volume><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2005.07.1292</pub-id><pub-id pub-id-type="pmid">16412740</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>N</given-names></name><name><surname>Uygur</surname><given-names>D</given-names></name><name><surname>Ozgu</surname><given-names>E</given-names></name><name><surname>Batioglu</surname><given-names>S</given-names></name></person-group><article-title>Does coasting, a procedure to avoid ovarian hyperstimulation syndrome, affect assisted reproduction cycle outcome?</article-title><source>Fertil Steril</source><year>2010</year><volume>94</volume><fpage>189</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2009.02.090</pub-id><pub-id pub-id-type="pmid">19376515</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delvigne</surname><given-names>A</given-names></name><name><surname>Rozenberg</surname><given-names>S</given-names></name></person-group><article-title>A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients</article-title><source>Hum Reprod Update</source><year>2002</year><volume>8</volume><fpage>291</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1093/humupd/8.3.291</pub-id><pub-id pub-id-type="pmid">12078839</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nardo</surname><given-names>LG</given-names></name><name><surname>Cheema</surname><given-names>P</given-names></name><name><surname>Gelbaya</surname><given-names>TA</given-names></name><name><surname>Horne</surname><given-names>G</given-names></name><name><surname>Fitzgerald</surname><given-names>CT</given-names></name><name><surname>Pease</surname><given-names>EH</given-names></name><name><surname>Brison</surname><given-names>DR</given-names></name><name><surname>Lieberman</surname><given-names>BA</given-names></name></person-group><article-title>The optimal length of &#x02018;coasting protocol&#x02019; in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization</article-title><source>Hum Fertil (Camb)</source><year>2006</year><volume>9</volume><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1080/14647270600787575</pub-id><pub-id pub-id-type="pmid">17008270</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatemi</surname><given-names>HM</given-names></name><name><surname>Popovic-Todorovic</surname><given-names>B</given-names></name><name><surname>Donoso</surname><given-names>P</given-names></name><name><surname>Papanikolaou</surname><given-names>E</given-names></name><name><surname>Smitz</surname><given-names>J</given-names></name><name><surname>Devroey</surname><given-names>P</given-names></name></person-group><article-title>Luteal phase oestradiol suppression by letrozole: a pilot study in oocyte donors</article-title><source>Reprod Biomed Online</source><year>2008</year><volume>17</volume><fpage>307</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/S1472-6483(10)60212-X</pub-id><pub-id pub-id-type="pmid">18764999</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Velasco</surname><given-names>JA</given-names></name><name><surname>Quea</surname><given-names>G</given-names></name><name><surname>Pir&#x000f3;</surname><given-names>M</given-names></name><name><surname>Mayoral</surname><given-names>M</given-names></name><name><surname>Ruiz</surname><given-names>M</given-names></name><name><surname>Toribio</surname><given-names>M</given-names></name><name><surname>Requena</surname><given-names>A</given-names></name></person-group><article-title>Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial</article-title><source>Fertil Steril</source><year>2009</year><volume>92</volume><fpage>222</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2008.04.042</pub-id><pub-id pub-id-type="pmid">18710719</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ujioka</surname><given-names>T</given-names></name><name><surname>Matsuura</surname><given-names>K</given-names></name><name><surname>Kawano</surname><given-names>T</given-names></name><name><surname>Okamura</surname><given-names>H</given-names></name></person-group><article-title>Role of progesterone in capillary permeability in hyperstimulated rats</article-title><source>Hum Reprod</source><year>1997</year><volume>12</volume><fpage>1629</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1093/humrep/12.8.1629</pub-id><pub-id pub-id-type="pmid">9308783</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>K</given-names></name><name><surname>Ohba</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><name><surname>Iqbal</surname><given-names>M</given-names></name><name><surname>Okamura</surname><given-names>Y</given-names></name><name><surname>Okamura</surname><given-names>H</given-names></name></person-group><article-title>Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats</article-title><source>Endocr J</source><year>2003</year><volume>50</volume><fpage>515</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1507/endocrj.50.515</pub-id><pub-id pub-id-type="pmid">14614207</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coccia</surname><given-names>ME</given-names></name><name><surname>Comparetto</surname><given-names>C</given-names></name><name><surname>Bracco</surname><given-names>GL</given-names></name><name><surname>Scarselli</surname><given-names>G</given-names></name></person-group><article-title>GnRH antagonists</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2004</year><volume>115</volume><issue>Suppl 1</issue><fpage>S44</fpage><lpage>S56</lpage><pub-id pub-id-type="doi">10.1016/j.ejogrb.2004.01.033</pub-id><pub-id pub-id-type="pmid">15196716</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pundir</surname><given-names>J</given-names></name><name><surname>Sunkara</surname><given-names>SK</given-names></name><name><surname>El-Toukhy</surname><given-names>T</given-names></name><name><surname>Khalaf</surname><given-names>Y</given-names></name></person-group><article-title>Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS?</article-title><source>Reprod Biomed Online</source><year>2012</year><volume>24</volume><issue>1</issue><fpage>6</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.rbmo.2011.09.017</pub-id><pub-id pub-id-type="pmid">22133908</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griesinger</surname><given-names>G</given-names></name><name><surname>Diedrich</surname><given-names>K</given-names></name><name><surname>Tarlatzis</surname><given-names>BC</given-names></name><name><surname>Kolibianakis</surname><given-names>EM</given-names></name></person-group><article-title>GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis</article-title><source>Reprod Biomed Online</source><year>2006</year><volume>13</volume><fpage>628</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1016/S1472-6483(10)60652-9</pub-id><pub-id pub-id-type="pmid">17169171</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonilla-Musoles</surname><given-names>FM</given-names></name><name><surname>Raga</surname><given-names>F</given-names></name><name><surname>Castillo</surname><given-names>JC</given-names></name><name><surname>Sanz</surname><given-names>M</given-names></name><name><surname>Dolz</surname><given-names>M</given-names></name><name><surname>Osborne</surname><given-names>N</given-names></name></person-group><article-title>High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome</article-title><source>Clin Exp Obstet Gynecol</source><year>2009</year><volume>36</volume><fpage>78</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">19688946</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lainas</surname><given-names>TG</given-names></name><name><surname>Sfontouris</surname><given-names>IA</given-names></name><name><surname>Zorzovilis</surname><given-names>IZ</given-names></name><name><surname>Petsas</surname><given-names>GK</given-names></name><name><surname>Lainas</surname><given-names>GT</given-names></name><name><surname>Kolibianakis</surname><given-names>EM</given-names></name></person-group><article-title>Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist</article-title><source>Reprod Biomed Online</source><year>2007</year><volume>15</volume><fpage>408</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/S1472-6483(10)60366-5</pub-id><pub-id pub-id-type="pmid">17908403</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lainas</surname><given-names>GT</given-names></name><name><surname>Kolibianakis</surname><given-names>EM</given-names></name><name><surname>Sfontouris</surname><given-names>IA</given-names></name><name><surname>Zorzovilis</surname><given-names>IZ</given-names></name><name><surname>Petsas</surname><given-names>GK</given-names></name><name><surname>Tarlatzi</surname><given-names>TB</given-names></name><name><surname>Tarlatzis</surname><given-names>BC</given-names></name><name><surname>Lainas</surname><given-names>TG</given-names></name></person-group><article-title>Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study</article-title><source>Reprod Biol Endocrinol</source><year>2012</year><volume>10</volume><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/1477-7827-10-69</pub-id><pub-id pub-id-type="pmid">22938051</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lainas</surname><given-names>GT</given-names></name><name><surname>Kolibianakis</surname><given-names>EM</given-names></name><name><surname>Sfontouris</surname><given-names>IA</given-names></name><name><surname>Zorzovilis</surname><given-names>IZ</given-names></name><name><surname>Petsas</surname><given-names>GK</given-names></name><name><surname>Lainas</surname><given-names>TG</given-names></name><name><surname>Tarlatzis</surname><given-names>BC</given-names></name></person-group><article-title>Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS</article-title><source>Hum Reprod</source><year>2013</year><volume>28</volume><fpage>1929</fpage><lpage>1942</lpage><pub-id pub-id-type="doi">10.1093/humrep/det114</pub-id><pub-id pub-id-type="pmid">23624582</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lainas</surname><given-names>GT</given-names></name><name><surname>Kolibianakis</surname><given-names>EM</given-names></name><name><surname>Sfontouris</surname><given-names>IA</given-names></name><name><surname>Zorzovilis</surname><given-names>IZ</given-names></name><name><surname>Petsas</surname><given-names>GK</given-names></name><name><surname>Lainas</surname><given-names>TG</given-names></name><name><surname>Tarlatzis</surname><given-names>BC</given-names></name></person-group><article-title>Serum vascular endothelial growth factor levels following luteal gonadotrophin- releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome</article-title><source>BJOG</source><year>2014</year><volume>121</volume><fpage>848</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1111/1471-0528.12572</pub-id><pub-id pub-id-type="pmid">24621101</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golan</surname><given-names>A</given-names></name><name><surname>Ron-el</surname><given-names>R</given-names></name><name><surname>Herman</surname><given-names>A</given-names></name><name><surname>Soffer</surname><given-names>Y</given-names></name><name><surname>Weinraub</surname><given-names>Z</given-names></name><name><surname>Caspi</surname><given-names>E</given-names></name></person-group><article-title>Ovarian hyperstimulation syndrome: an update review</article-title><source>Obstet Gynecol Surv</source><year>1989</year><volume>44</volume><fpage>430</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1097/00006254-198906000-00004</pub-id><pub-id pub-id-type="pmid">2660037</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delvigne</surname><given-names>A</given-names></name></person-group><article-title>Symposium: Update on prediction and management of OHSS. Epidemiology of OHSS</article-title><source>Reprod Biomed Online</source><year>2009</year><volume>19</volume><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/S1472-6483(10)60040-5</pub-id><pub-id pub-id-type="pmid">19573285</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatemi</surname><given-names>HM</given-names></name></person-group><article-title>The luteal phase after 3 decades of IVF: what do we know?</article-title><source>Reprod Biomed Online</source><year>2009</year><volume>19</volume><issue>4</issue><fpage>4331</fpage><pub-id pub-id-type="pmid">20034417</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fauser</surname><given-names>BC</given-names></name><name><surname>Devroey</surname><given-names>P</given-names></name></person-group><article-title>Reproductive biology and IVF: ovarian stimulation and luteal phase consequences</article-title><source>Trends Endocrinol Metab</source><year>2003</year><volume>14</volume><fpage>236</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/S1043-2760(03)00075-4</pub-id><pub-id pub-id-type="pmid">12826330</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavaniotou</surname><given-names>A</given-names></name><name><surname>Bourgain</surname><given-names>C</given-names></name><name><surname>Albano</surname><given-names>C</given-names></name><name><surname>Platteau</surname><given-names>P</given-names></name><name><surname>Smitz</surname><given-names>J</given-names></name><name><surname>Devroey</surname><given-names>P</given-names></name></person-group><article-title>Endometrial integrin expression in the early luteal phase in natural and stimulated cycles for in vitro fertilization</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2003</year><volume>108</volume><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/S0301-2115(02)00428-1</pub-id><pub-id pub-id-type="pmid">12694973</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enskog</surname><given-names>A</given-names></name><name><surname>Henriksson</surname><given-names>M</given-names></name><name><surname>Unander</surname><given-names>M</given-names></name><name><surname>Nilsson</surname><given-names>L</given-names></name><name><surname>Br&#x000e4;nnstr&#x000f6;m</surname><given-names>M</given-names></name></person-group><article-title>Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization</article-title><source>Fertil Steril</source><year>1999</year><volume>71</volume><fpage>808</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1016/S0015-0282(99)00090-4</pub-id><pub-id pub-id-type="pmid">10231037</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aboulghar</surname><given-names>M</given-names></name></person-group><article-title>Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS</article-title><source>Hum Reprod</source><year>2003</year><volume>18</volume><fpage>1140</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1093/humrep/deg208</pub-id><pub-id pub-id-type="pmid">12773437</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelan</surname><given-names>JG</given-names></name><name><surname>Vlahos</surname><given-names>NF</given-names></name></person-group><article-title>The ovarian hyperstimulation syndrome</article-title><source>Fertil Steril</source><year>2000</year><volume>73</volume><fpage>883</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1016/S0015-0282(00)00491-X</pub-id><pub-id pub-id-type="pmid">10785212</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>PA</given-names></name><name><surname>Robinson</surname><given-names>CH</given-names></name></person-group><article-title>Mechanism and inhibition of cytochrome P-450 aromatase</article-title><source>J Med Chem</source><year>1990</year><volume>33</volume><fpage>2933</fpage><lpage>2942</lpage><pub-id pub-id-type="doi">10.1021/jm00173a001</pub-id><pub-id pub-id-type="pmid">2231592</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winer</surname><given-names>EP</given-names></name><name><surname>Hudis</surname><given-names>C</given-names></name><name><surname>Burstein</surname><given-names>HJ</given-names></name><name><surname>Chlebowski</surname><given-names>RT</given-names></name><name><surname>Ingle</surname><given-names>JN</given-names></name><name><surname>Edge</surname><given-names>SB</given-names></name><name><surname>Mamounas</surname><given-names>EP</given-names></name><name><surname>Gralow</surname><given-names>J</given-names></name><name><surname>Goldstein</surname><given-names>LJ</given-names></name><name><surname>Pritchard</surname><given-names>KI</given-names></name><name><surname>Braun</surname><given-names>S</given-names></name><name><surname>Cobleigh</surname><given-names>MA</given-names></name><name><surname>Langer</surname><given-names>AS</given-names></name><name><surname>Perotti</surname><given-names>J</given-names></name><name><surname>Powles</surname><given-names>TJ</given-names></name><name><surname>Whelan</surname><given-names>TJ</given-names></name><name><surname>Browman</surname><given-names>GP</given-names></name></person-group><article-title>American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>3317</fpage><lpage>3327</lpage><pub-id pub-id-type="doi">10.1200/JCO.2002.06.020</pub-id><pub-id pub-id-type="pmid">12149306</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Velasco</surname><given-names>JA</given-names></name><name><surname>Moreno</surname><given-names>L</given-names></name><name><surname>Pacheco</surname><given-names>A</given-names></name><name><surname>Guill&#x000e9;n</surname><given-names>A</given-names></name><name><surname>Duque</surname><given-names>L</given-names></name><name><surname>Requena</surname><given-names>A</given-names></name><name><surname>Pellicer</surname><given-names>A</given-names></name></person-group><article-title>The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study</article-title><source>Fertil Steril</source><year>2005</year><volume>84</volume><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2005.01.117</pub-id><pub-id pub-id-type="pmid">16009161</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitwally</surname><given-names>MF</given-names></name><name><surname>Casper</surname><given-names>RF</given-names></name></person-group><article-title>Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation</article-title><source>J Soc Gynecol Investig</source><year>2004</year><volume>11</volume><fpage>406</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/j.jsgi.2004.03.006</pub-id><pub-id pub-id-type="pmid">15350255</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuen</surname><given-names>BH</given-names></name><name><surname>McComb</surname><given-names>P</given-names></name><name><surname>Sy</surname><given-names>L</given-names></name><name><surname>Lewis</surname><given-names>J</given-names></name><name><surname>Cannon</surname><given-names>W</given-names></name></person-group><article-title>Plasma prolactin, human chorionic gonadotropin, estradiol, testosterone, and progesterone in the ovarian hyperstimulation syndrome</article-title><source>Am J Obstet Gynecol</source><year>1979</year><volume>133</volume><fpage>316</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">433993</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spitz</surname><given-names>LM</given-names></name><name><surname>Croxatto</surname><given-names>HB</given-names></name><name><surname>L&#x000e4;hteenm&#x000e4;ki</surname><given-names>P</given-names></name><name><surname>Heikinheimo</surname><given-names>O</given-names></name><name><surname>Bardin</surname><given-names>CW</given-names></name></person-group><article-title>Effect of mifepriston on inhibition of ovulation and induction of luteolysis</article-title><source>Hum Reprod</source><year>1994</year><volume>9</volume><issue>suppl 1</issue><fpage>1069</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1093/humrep/9.suppl_1.69</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnoth</surname><given-names>C</given-names></name><name><surname>Halbe</surname><given-names>E</given-names></name><name><surname>Freundl</surname><given-names>G</given-names></name></person-group><article-title>Persistent ascites after ovarian hyperstimula-tion syndrome and administration of mifepristone (RU 486) for the termination of pregnancy</article-title><source>Arch Gynecol Obstet</source><year>2003</year><volume>268</volume><fpage>65</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">12673480</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yung</surname><given-names>Y</given-names></name><name><surname>Maman</surname><given-names>E</given-names></name><name><surname>Ophir</surname><given-names>L</given-names></name><name><surname>Rubinstein</surname><given-names>N</given-names></name><name><surname>Barzilay</surname><given-names>E</given-names></name><name><surname>Yerushalmi</surname><given-names>GM</given-names></name><name><surname>Hourvitz</surname><given-names>A</given-names></name></person-group><article-title>Progesterone antagonist, RU486, represses LHCGR expression and LH/hCG signaling in cultured luteinized human mural granulosa cells</article-title><source>Gynecol Endocrinol</source><year>2014</year><volume>30</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.3109/09513590.2013.848426</pub-id><pub-id pub-id-type="pmid">24147854</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devoto</surname><given-names>L</given-names></name><name><surname>Vega</surname><given-names>M</given-names></name><name><surname>Kohen</surname><given-names>P</given-names></name><name><surname>Castro</surname><given-names>A</given-names></name><name><surname>Castro</surname><given-names>O</given-names></name><name><surname>Christenson</surname><given-names>LK</given-names></name><name><surname>Carvallo</surname><given-names>P</given-names></name><name><surname>Strauss</surname><given-names>JF</given-names><suffix>3rd</suffix></name></person-group><article-title>Endocrine and paracrine-autocrine regulation of the human corpus luteum during the mid-luteal phase</article-title><source>J Reprod Fertil Suppl</source><year>2000</year><volume>55</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">10889830</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casper</surname><given-names>RF</given-names></name><name><surname>Yen</surname><given-names>SS</given-names></name></person-group><article-title>Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor</article-title><source>Science</source><year>1979</year><volume>205</volume><fpage>408</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1126/science.377491</pub-id><pub-id pub-id-type="pmid">377491</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mais</surname><given-names>V</given-names></name><name><surname>Kazer</surname><given-names>RR</given-names></name><name><surname>Cetel</surname><given-names>NS</given-names></name><name><surname>Rivier</surname><given-names>J</given-names></name><name><surname>Vale</surname><given-names>W</given-names></name><name><surname>Yen</surname><given-names>SS</given-names></name></person-group><article-title>The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin-releasing hormone antagonist as a probe</article-title><source>J Clin Endocrinol Metab</source><year>1986</year><volume>62</volume><fpage>1250</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.1210/jcem-62-6-1250</pub-id><pub-id pub-id-type="pmid">3084538</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortmann</surname><given-names>O</given-names></name><name><surname>Weiss</surname><given-names>JM</given-names></name><name><surname>Diedrich</surname><given-names>K</given-names></name></person-group><article-title>Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists</article-title><source>Hum Reprod</source><year>2001</year><volume>16</volume><fpage>608</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1093/humrep/16.4.608</pub-id><pub-id pub-id-type="pmid">11278203</pub-id></element-citation></ref></ref-list></back></article>